Apr 22nd, 10:00 AM - 4:00 PM

Long-Term Effectiveness of Combined Alprazolam and Cognitive-Behavioral Therapies in Panic Disorder

Steven M. Bond, '95
Illinois Wesleyan University

Timothy J. Bruce, Faculty Advisor
University of Illinois College of Medicine, Peoria

Follow this and additional works at: http://digitalcommons.iwu.edu/jwprc


This Event is brought to you for free and open access by The Ames Library, the Andrew W. Mellon Center for Curricular and Faculty Development, the Office of the Provost and the Office of the President. It has been accepted for inclusion in Digital Commons @ IWU by the faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.

©Copyright is owned by the author of this document.
LONG-TERM EFFECTIVENESS OF COMBINED ALPRAZOLAM AND COGNITIVE-BEHAVIORAL THERAPIES IN PANIC DISORDER

Steven M. Bond, Department of Psychology, IWU and Timothy J. Bruce', Department of Psychiatry, UICOMP

Benzodiazepines, particularly alprazolam, have been shown to be effective in the treatment of panic disorder. However, difficult withdrawal and high relapse rates after successful discontinuation continue to be problems with this class of medication. Recent studies instituting cognitive-behavioral therapy as a treatment supplement to alprazolam taper have shown promising results at short-term follow-up. The present study investigated whether these procedures produce long-term (two- to four-year) improvement. Patients were stabilized on alprazolam and randomly assigned to either an alprazolam-only group or the same condition with twelve weeks of concurrent cognitive-behavioral therapy. Twenty patients who completed these treatments were assessed at two- to four-year follow-up. In addition to the discontinuation success rates, self-report and clinician-rated measures concerning panic attack frequency, disability intensity, agoraphobic avoidance, and anxiety severity were used to evaluate relapse. Preliminary analysis of clinician-rated assessments suggests that patients receiving combined therapy were clinically improved at long-term follow-up in comparable percentages to previously published data. Results and clinical implications for combined alprazolam and cognitive-behavioral therapy will be discussed at the conference.